Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Liang-Wei TsengJohn Wen-Cheng ChangChiao-En WuPublished in: International journal of molecular sciences (2022)
The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and tepotinib. The safety of treating a patient with a MET inhibitor after drug-induced pneumonitis by another MET inhibitor remains unclear. Here, we present a case of a patient with NSCLC harboring a METex14 who was treated with a standard dose of tepotinib after advanced capmatinib-induced pneumonitis and did not present pneumonitis relapse. Tepotinib may be a safe option when medical professionals consider switching MET inhibitors after patients experience pneumonitis.
Keyphrases
- drug induced
- liver injury
- interstitial lung disease
- tyrosine kinase
- case report
- small cell lung cancer
- adverse drug
- end stage renal disease
- newly diagnosed
- systemic sclerosis
- healthcare
- chronic kidney disease
- advanced non small cell lung cancer
- rheumatoid arthritis
- prognostic factors
- emergency department
- idiopathic pulmonary fibrosis
- oxidative stress
- combination therapy
- drug delivery